Interventional Glaucoma

The 18th annual Controversies in Modern Eye Care conference, held on May 4, 2024, in Los Angeles, was co-chaired by Neda Shamie, MD, and Arjan Hura, MD, with the aim of discussing the latest advancements in eye care.

Rick Lewis, chief medical officer of ViaLase, describes the company's nonincisional glaucoma treatment, showing promising safety and efficacy in studies and possibly paving the way for FDA approval.

Alcon was ordered to pay $34 million to Sight Sciences after a trial by jury.

Deborah Gess Ristvedt, DO, shares highlights from her presentation and what these real-world cases mean for clinicians and their patients with glaucoma.

David Lubeck, MD, talks about the biggest surprises from ASCRS in the glaucoma space

Dr Nir Shoham-Hazon presented two papers detailing outcomes from the iTrack microcatheter at ASCRS in Boston

UPFs include fast food, energy drinks and soda, sweets such as chocolates and candies and much more.

At ASCRS, Dr Rom Kandavel discusses iStent outcomes for patients who have undergone laser peripheral iridotomy, trabeculectomy and SLT

The switch may produce an additional 25% IOP reduction in mild to moderate forms of disease

At ASCRS in Boston, Paul Harasymowycz, MD shared a decade's worth of data on MIGS procedures for primary open-angle glaucoma

Mark J. Gallardo, MD, highlighted the results from a phase 2 clinical trial of a travoprost intracameral implant in open-angle glaucoma or ocular hypertension.

The technology uses a superelastic, memory-shaped nitinol guide that facilitates up to 360-degree guided circumferential removal of the trabecular meshwork.

The investigators conducted a multicenter, prospective, open-label, phase 4 study in which they evaluated the patients’ and investigators’ impressions of the drug.

The Osprey trial has started dosing while the Apteryx trial is anticipated to begin within the next few weeks.

One year after implantation, the enduring IOP reduction remained consistent across all 3 dose strengths.

The audiobook of GRF's flagship 40-page educational booklet "Understanding and Living with Glaucoma is narrated by Bianca Beach, an actress, advocate, and glaucoma patient.

The glaucoma specialist talks about navigating the world of research, and the realities of motherhood, as a clinician

Results from the trial by Nannodropper show microdrops could reduce waste, cost, and side effects while being as effective as traditional size drops.

Proteins common to Alzheimer disease play a significant role in glaucoma

According to the company, NCX 470 is a novel NO-donating bimatoprost eye drop, is currently in Phase 3 clinical development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.

According to the foundation, the grants were awarded to 18 investigators at prominent universities in the United States, Nigeria, and Hong Kong.

Neda Shamie, MD, previews a collaborative day packed with guest speakers, discussions on advanced patient care, and hands-on labs.

LL-BMT1 is a novel, preservative-free, weekly drug-eluting contact lens created by the company’s proprietary 3D printing technology.

Study concluded that the short-term results of LBN to treat mild-to-modern OAG and OHT was safe and efficacious.

Andrew G. Iwach, MD, recounts two personal life experiences that underscore the significance of patient-centered care in glaucoma management.